{
    "name": "voretigene neparvovec",
    "comment": "Rx",
    "other_names": [
        "Luxturna",
        "voretigene neparvovec-rzyl"
    ],
    "classes": [
        "Retinal Gene Therapies"
    ],
    "source": "https://reference.medscape.com/drug/luxturna-voretigene-neparvovec-1000197",
    "pregnancy": {
        "common": [
            "Well-controlled human and animal reproductive studies with voretigene neparvovex-rzyl have not been conducted in pregnant women",
            "No nonclinical or clinical studies were performed to evaluate the effect of voretigene neparvovex-rzyl on fertility"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "No information regarding the presence of voretigene neparvovex-rzyl in human milk, the effects on the breastfed infant, or the effects on milk production",
            "Development and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for voretigene neparvovex-rzyl and any potential adverse effects on the breastfed infant from voretigene neparvovex-rzyl"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Endophthalmitis may occur following any intraocular surgical procedure or injection; monitor and advise any signs or symptoms of infection or inflammation without delay",
                "Permanent decline in visual acuity may occur following subretinal injection; monitor for visual disturbances",
                "Retinal abnormalities (eg, macular holes, foveal thinning, loss of foveal function, foveal dehiscence, retinal hemorrhage) may occur; monitor and manage retinal abnormalities appropriately; do not administer voretigene neparvovex-rzyl in the immediate vicinity of the fovea",
                "During or following vitrectomy, retinal abnormalities (eg, retinal tears, epiretinal membrane, retinal detachment) may occur; monitor during and following injection to permit early treatment of these retinal abnormalities; advise patients to report any signs or symptoms of retinal tears and/or detachment without delay",
                "Increased intraocular pressure may occur",
                "Avoid air travel, travel to high elevation or scuba diving until the air bubble formed following administration has completely dissipated from the eye; may take >1 week or more following injection for the air bubble to dissipate; changes in altitude while the air bubble is still present can result in irreversible vision loss",
                "Subretinal injection of voretigene neparvovex-rzyl, especially vitrectomy surgery, is associated with an increased incidence of cataract development and/or progression"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Incidence based on by number of eyes treated",
            "percent": "19"
        },
        {
            "name": "Cataract",
            "percent": "11"
        },
        {
            "name": "Conjunctival hyperemia",
            "percent": "10"
        },
        {
            "name": "Incidence based on by number of eyes treated",
            "percent": "5"
        },
        {
            "name": "Increased intraocular pressure",
            "percent": "5"
        },
        {
            "name": "Retinal tear",
            "percent": "4"
        },
        {
            "name": "Eye inflammation",
            "percent": "4"
        },
        {
            "name": "Dellen",
            "percent": "4"
        },
        {
            "name": "thinning of the corneal stroma",
            "percent": "4"
        },
        {
            "name": "Macular hole",
            "percent": "2"
        },
        {
            "name": "Subretinal deposits",
            "percent": "2"
        },
        {
            "name": "Maculopathy",
            "percent": "2"
        },
        {
            "name": "wrinkling on the surface of the macula",
            "percent": "1"
        },
        {
            "name": "Eye irritation",
            "percent": "1"
        },
        {
            "name": "Eye pain",
            "percent": "1"
        },
        {
            "name": "Foveal thinning and loss of function",
            "percent": null
        },
        {
            "name": "Endophthalmitis",
            "percent": null
        },
        {
            "name": "Fovea dehiscence",
            "percent": null
        },
        {
            "name": "separation of the retinal layers in the center of the macula",
            "percent": null
        },
        {
            "name": "Retinal hemorrhage",
            "percent": null
        },
        {
            "name": "Eye disorders",
            "percent": null
        },
        {
            "name": "Chorioretinal atrophy",
            "percent": null
        },
        {
            "name": "also reported as retinal degeneration",
            "percent": null
        },
        {
            "name": "retinal depigmentation",
            "percent": null
        },
        {
            "name": "and injection site atrophy",
            "percent": null
        }
    ]
}